Duchenne muscular dystrophy: major trials and events to watch in 2023 [Yahoo! Finance]
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: Yahoo! Finance
In 2023, two potential FDA approvals and three late-stage clinical trial readouts could shift the treatment landscape for Duchenne muscular dystrophy. The upcoming FDA approval decision for Sarepta's gene therapy SRP-9001, expected by May, headlines what figures to be an eventful year of drug development. In addition to the looming approval decision for SRP-9001, Santhera's and ReveraGen's synthetic steroid vamorolone could receive FDA approval in October. Meanwhile, FibroGen's antibody pamrevlumab and Capricor's stem cell therapy CAP-1002 both expect Phase III data by mid-2023, and Edgewise's EDG-5506 has Phase II data expected by the end of the year. The wide variety of mechanisms and development stages means these investigational therapies have a range of approval prospects, according to GlobalData's Likelihood of Approval algorithm. GlobalData, the parent company of Clinical Trials Arena , evaluates the Likelihood of Approval using a combination of machine learning and a prop
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- FibroGen, Inc. (NASDAQ: FGEN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
FGEN
Earnings
- 11/12/24 - Beat
FGEN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- 1/10/25 - Form 4
- FGEN's page on the SEC website